Kurmangaliyeva Saulesh, Madenbayeva Akzhan, Urazayeva Saltanat, Baktikulova Kristina, Kurmangaliyev Kairat
Department of Microbiology, Virology and Immunology, West Kazakhstan Marat Ospanov Medical University, Aktobe, Republic of Kazakhstan.
Department of Epidemiology, West Kazakhstan Marat Ospanov Medical University, Aktobe, Republic of Kazakhstan.
Qatar Med J. 2025 Feb 23;2025(1):6. doi: 10.5339/qmj.2025.6. eCollection 2025.
The post-COVID-19 syndrome may present with a range of neurological symptoms such as headaches, sleep disorders, and dizziness. The objective of this study was to examine the effectiveness of the Gam-COVID-Vac vaccine in mitigating the neurological symptoms of post-COVID-19 syndrome. The study involved 95 patients diagnosed with the neurological form of long COVID-19, who were divided into two groups according to their vaccination status. The immunological parameters of humoral immunity were evaluated by enzyme-linked immunosorbent assay (ELISA), while the parameters of cellular immunity were evaluated using flow cytometry. Administration of the vaccination resulted in a reduction in clinical symptoms of the neurological form of long COVID-19. Statistically significant differences ( = 0.035) were found in symptoms such as headaches, sleep disturbances, and dizziness, especially in central nervous system (CNS) disorders, between the groups that received the vaccination and those that did not. More than 90% of patients had elevated levels of Receptor Binding Domain (RBD) immunoglobulin G against the viral S-protein (>2,500 BAU/ml), indicating strong humoral immunity regardless of vaccination status. An increase in B-lymphocyte (CD3CD19) counts was noted in both groups, with levels significantly higher in the group that received the vaccination ( < 0.03). Analysis of T-cell profiles and NK (natural killer) cell levels showed no changes. The study suggests that administration of Gam-COVID-Vac vaccination could reduce the occurrence of CNS symptoms in individuals with post-COVID-19 syndrome. Although certain neurological symptoms may continue, immunization has a beneficial influence on their progression. The results emphasize the crucial role of an increased humoral immune response in individuals with post-COVID-19 syndrome, but do not show significant changes in T-cell immune parameters.
新冠后综合征可能会出现一系列神经症状,如头痛、睡眠障碍和头晕。本研究的目的是检验Gam-COVID-Vac疫苗在减轻新冠后综合征神经症状方面的有效性。该研究纳入了95名被诊断为患有长期新冠神经症状形式的患者,他们根据疫苗接种状况被分为两组。采用酶联免疫吸附测定(ELISA)评估体液免疫的免疫参数,同时使用流式细胞术评估细胞免疫参数。接种疫苗后,长期新冠神经症状形式的临床症状有所减轻。在接受疫苗接种和未接种疫苗的两组之间,在头痛、睡眠障碍和头晕等症状,尤其是中枢神经系统(CNS)疾病方面,发现了具有统计学意义的差异(P = 0.035)。超过90%的患者针对病毒S蛋白的受体结合域(RBD)免疫球蛋白G水平升高(>2500 BAU/ml),表明无论疫苗接种状况如何,体液免疫都很强。两组均观察到B淋巴细胞(CD3CD19)计数增加,接种疫苗组的水平显著更高(P < 0.03)。T细胞谱和NK(自然杀伤)细胞水平分析未显示变化。该研究表明,接种Gam-COVID-Vac疫苗可减少新冠后综合征患者中枢神经系统症状的发生。虽然某些神经症状可能会持续存在,但免疫接种对其进展有有益影响。结果强调了体液免疫反应增强在新冠后综合征患者中的关键作用,但未显示T细胞免疫参数有显著变化。